Alflorex® News → B. longum 35624

Abstracts analysis summary

🌀 No 35624/Alflorex-specific papers in this batch. Highlighting the most clinically relevant B. longum papers in gut–brain and GI interaction.

🌀 Distinct Microbiome Signatures and Therapeutic Role of Bifidobacterium longum in Pediatric Migraine 🧪🧠

🔥 Main in 3 points

Pediatric migraine patients had decreased B. longum and more severe GI symptoms, higher headache disability, and calprotectin if GI disorder co-occurred.
B. longum supplementation in both animal models and a pediatric pilot study reduced headache days, frequency, and intensity.
Gut–brain axis modulation via B. longum linked to milder disease and decreased neuroinflammation.

🧪 Context

Prospective stool microbiota profiling (n=126 migraine pts, 50 controls, 6–19 yrs) and pilot B. longum supplementation (n=23) with Rome IV GI phenotyping, neurologic symptom and biomarker analyses.

📍 Practical significance

Consider screening for gut symptoms and B. longum depletion in pediatric migraineurs with GI complaints. B. longum supplementation may benefit those with pronounced gut–brain axis involvement and abdominal symptoms.

🔗 PubMed doi:10.1080/19490976.2025.2606487

❓ Can probiotic B. longum-based regimens support cognitive function in ADHD? 🧠🧪

✅ Study answer

In children (n=84) with ADHD, a 2-month probiotic (incl. B. longum) course significantly improved executive function scores (BRIEF total 151.5 ±16.8 vs. placebo 190.7 ±23.5; F=7.93, p<0.001).
Safety was comparable to placebo, with no major adverse events.

📍 How to apply

Children with ADHD and mild executive dysfunction may experience measurable benefit from multi-strain probiotics (containing B. longum, B. lactis, L. acidophilus) as adjunctive therapy. Consider at least 2 months of supplementation before reassessment.

🔗 PubMed doi:10.1002/npr2.70084

🧾 Pediatric recurrent UTIs: Probiotic, cranberry & Vitamin C supplement outcomes 👥✅

✅ Do

Consider 6-month combined therapy (including B. longum, L. rhamnosus) for children with recurrent UTIs, including those with vesicoureteral reflux.
Expect median UTI episodes to drop from 2–3 before to zero after intervention; 69% remained infection-free through 1-year follow-up.

⚠️ With caution

Mild GI symptoms (12.8%) may occur, but no serious AEs reported.

🚫 Avoid

Not a substitute for acute UTI therapy; not tested in severe VUR.

🔗 PubMed doi:10.1080/19390211.2026.2615923

🧪 Intestinal Barrier Dysfunction in Sepsis: B. longum-reactive T Helper Cells as a Blood Marker 📊🧫

🧪 What was studied

70 ICU pts (sepsis, non-sepsis, COVID-19) vs. 20 healthy; peripheral T helper cell enrichment assays.

📈 Key results

Expansion of B. longum–reactive T-helper cells in sepsis, signifying intestinal barrier impairment.

📍 What this changes in practice

Blood-based detection of B. longum-reactive T-cells may serve as a real-time, noninvasive marker for gut barrier function in critical illness, aiding monitoring of interventions for intestinal permeability.

🔗 PubMed doi:10.1186/s13099-025-00770-9

🧠 Gut Microbiome Links to Childhood Asthma: Role of B. longum and Host Genetics 🧬📈

🔥 Main in 3 points

B. longum abundance correlated with better FEV1/FVC in children with prior bronchiolitis.
Protective associations between particular microbes (B. longum, R. bromii) and asthma indices notably in children with high polygenic risk scores.
Gut–host genetic interaction shapes asthma susceptibility and lung function.

🧪 Context

Cross-sectional multicenter study, n=300, deep metagenomics with host genetics.

📍 Practical significance

Future directions: microbiome profiling (including B. longum status) may guide asthma risk stratification and individualized prevention in genetically susceptible children.

🔗 PubMed doi:10.1016/j.jaci.2025.12.1005